Core Viewpoint - The company, Dize (Jiangsu) Pharmaceutical Co., Ltd., is advancing its international capital strategy by approving the issuance of H-shares and plans for listing on the Hong Kong Stock Exchange, marking a significant step in its growth and expansion [1] Group 1: Shareholder Meeting Decisions - The company held its first extraordinary general meeting of 2026 on January 9, where multiple important resolutions were approved [1] - Key decisions included the approval of the H-share issuance plan, amendments to the company’s articles of association, and changes to registered capital to facilitate the listing [1] - The meeting also approved the distribution plan for retained earnings prior to the issuance, the appointment of a listing audit firm, and the establishment of a primary business address in Hong Kong [1] Group 2: Voting and Approval Details - The resolutions were supported by shareholders holding 64.4445% of the total voting rights, with all proposals receiving high approval [1] - Eight resolutions related to the H-share issuance and amendments to the articles of association were passed as special resolutions, each receiving over two-thirds approval from the voting rights present [1] Group 3: Strategic Implications - The decisions made during the shareholder meeting lay a crucial legal and decision-making foundation for the company's Hong Kong listing plan [1] - This marks an important milestone in the company's internationalization efforts and capital strategy [1]

Group 1 - The core point of the article is that Jucheng Semiconductor Co., Ltd. plans to issue overseas listed foreign shares (H shares) and list on the Main Board of the Hong Kong Stock Exchange [1] - The company will hold an extraordinary general meeting on January 16, 2026, to review and approve a series of related proposals, including the listing plan and fundraising usage plan [1] - The number of H shares to be issued will not exceed 15% of the total share capital after issuance, and the issuance price will be determined through a market-oriented pricing method [1] Group 2 - The raised funds, after deducting issuance costs, will primarily be used to enhance core technology capabilities and process platform construction, expand the product matrix, improve overseas layout, strategic investments and acquisitions, and supplement working capital [1] - To support this listing, the company's board structure will be adjusted, with the proposed appointment of Mao Zhenhua and Sun Kai as independent directors of the third board [1] - The resolutions related to this issuance and listing will be valid for 24 months from the date of approval by the shareholders' meeting, with an automatic extension until the completion date of the listing if required regulatory filings or approvals are obtained during this period [1] Group 3 - This move signifies Jucheng's formal initiation of an international capital strategy while consolidating its position on the Sci-Tech Innovation Board, aiming to broaden financing channels and enhance capital strength to accelerate its global business expansion [1]